VivoSeq
Other

Intelligence

14

Pipeline Programs

5

Active Trials

11

Companies Involved

Intelligence is an emerging landscape with 14 programs across 11 companies. The most active players are McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc., Pfizer's Upjohn has merged with Mylan to form Viatris Inc., Bayer. 5 therapies are approved with 1 more in late-stage development.

Pipeline Metrics

Competitive Density

43/100

Pipeline Velocity

25/100

Mech. Concentration

33/100

Completion Rate

90/100

Attrition Rate

6/100

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Programs by Phase

Trial Status

18

clinical trials

Completed9 · 50%
Recruiting3 · 17%
Unknown status3 · 17%
Active, not recruiting1 · 6%
Terminated1 · 6%
Not yet recruiting1 · 6%

Trial Activity

18 trials

Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)